Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment
Status:
Completed
Trial end date:
2018-03-22
Target enrollment:
Participant gender:
Summary
A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral
dose of GBT440 administered in subjects with mild (Child-Pugh A), moderate (Child-Pugh B), or
severe (Child-Pugh C) hepatic impairment disease and healthy subjects with normal hepatic
function.